Fig. 2: Association of PAM50NC_2nd subtype with patient outcome.
From: Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer
a Overall survival (OS) for endocrine-treated ERpHER2nLNn patients >50 years of age that were PAM50NC subtyped as LumANC. Patients are stratified by their PAM50NC_2nd subtype. b Overall survival for endocrine-treated ERpHER2nLNn patients >50 years of age that were PAM50NC subtyped as LumBNC. Patients are stratified by their PAM50NC_2nd subtype. c Distributions for age at diagnosis (left), tumor size (center), and ROR T0 scores (right) obtained from ref. 14 in endocrine-treated ERpHER2nLNn patients >50 years of age comparing cases subtyped as LumANC – LumBNC_2nd versus LumANC – NormalNC_2nd. d Distributions for age at diagnosis (left), tumor size (center), and ROR T0 scores (right) obtained from ref. 14 in endocrine-treated ERpHER2nLNn patients >50 years of age comparing cases subtyped as LumBNC – HER2ENC_2nd versus LumBNC – LumANC_2nd. e Overall survival for endocrine-treated ERpHER2nLNn patients >50 years of age that were PAM50NC subtyped as LumANC and as ROR-low risk category according to ref. 14. Patients are stratified by their PAM50NC_2nd subtype. f Overall survival for endocrine-treated ERpHER2nLNn patients >50 years of age that were PAM50NC subtyped as LumBNC and as ROR-high risk category according to ref. 14. Patients are stratified by their PAM50NC_2nd subtype. Boxplot elements correspond to: (1) center line = median, (2) box limits = upper and lower quartiles, (3) whiskers = 1.5x interquartile range.
